Glenmark Pharma gets final USFDA nod for migraine drug


Posted on:16 Mar 2016 15:07:18

Glenmark Pharma gets final USFDA nod for migraine drug
16 March 2016 Current Affairs: GlenmarkBSE 1.46 % Pharma has received final nod from the USFDA to manufacture and market therapeutical equivalent of Endo Pharmaceutical's Frova tablets, used to treat migraine headaches, in the US market. Glenmark Pharmaceuticals Inc has been granted final approval by the US Food and Drug Administration (USFDA) for Frovatriptan Succinate Tablets, 2.5 mg.the drug is "therapeutical equivalent of Endo Pharmaceutical's Frova tablets 2.5 mg." Quoting IMS data, Glenmark said the approved product has an estimated market size of $87.8 million for the 12 months ended January 2016. The company's current portfolio consists of 61 ANDAs pending approvals from the USFDA and 108 products authorised for distribution in the US. Glenmark Pharmaceuticals is a pharmaceutical company headquartered in Mumbai, India.It manufactures and markets generic formulation products and active pharmaceutical ingredients, both in the domestic and international markets.The company's current portfolio consists of 61 ANDAs pending approvals from the USFDA and 108 products authorised for distribution in the US.


Subscribe to Current Affairs

Enter your email to get daily current affairs

Current Affairs May 2017

29 MAY
NEWS
27 MAY
NEWS
26 MAY
NEWS
25 MAY
NEWS

Current Affairs April 2017

29 APRIL
NEWS
28 APRIL
NEWS
27 APRIL
NEWS
26 APRIL
NEWS

Current Affairs March 2017

31 MARCH
NEWS
30 MARCH
NEWS
29 MARCH
NEWS
28 MARCH
NEWS